In patients with newly diagnosed extranodal natural killer/T-cell (NK/T) lymphoma, first-line programmed death-1 (PD-1) inhibitors combined with asparaginase-based chemotherapy were associated with ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...

Association of AI-informed biomarkers of spatial organization of tumor-infiltrating lymphocytes with loco-regional recurrence in laryngeal squamous cell cancer. This is an ASCO Meeting Abstract from ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending ...

CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated ...

The Oncologic Drugs Advisory Committee (ODAC) decided 10-2 with one abstention that PD-1 inhibitors do not have a favorable risk/benefit profile in gastric/gastroesophageal junction (GEJ) cancers with ...

Delivering drugs to gut tumors can be tricky. Researchers at Washington University in St. Louis have engineered an oral probiotic yeast to do the work for them, with the fungal cells able to release ...

Efficacy and safety of anti-PD-1 combined with thymosin and SOX in neoadjuvant treatment of cStage III gastric or esophagogastric junctional adenocarcinoma (NAPTSOX24): A prospective, open-label, ...

Chinese patients with advanced acral melanoma achieved a small but significant increase in progression-free survival when treated with toripalimab versus dacarbazine. While the overall response rate ...

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...